Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.8K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.8K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.6K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.6K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

1.3K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.8K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantification of olaparib in human liver microsomes using an ultra-fast UPLC-MS/MS quantitative approach: <i>in vitro</i> and <i>in silico</i> metabolic stability assessment.

The Analyst·2026
Same author

Design, regioselective, time gated synthesis of novel benzo[d]imidazole analogues as potential quorum sensing inhibitors targeting LasR in Pseudomonas aeruginosa.

Bioorganic chemistry·2026
Same author

Quantification of buparlisib in human liver microsomes employing an ultra-fast, sensitive UPLC-MS/MS method: <i>in vitro</i> and <i>in silico</i> metabolic stability evaluation.

The Analyst·2026
Same author

Assessment of Apalutamide Metabolic Stability in HLMs Matrix Using a Sensitive and Fast UPLC-MS/MS Method: In Silico Screening for Toxicity Alerts and Metabolic Lability.

Biomedical chromatography : BMC·2026
Same author

What a Difference a Water Molecule Makes-A Combined Experimental/Theoretical Study on 2,3,5-triphenyl-2<i>H</i>-tetrazol-3-ium Chloride Hydrate in Solution and the Solid-State.

Molecules (Basel, Switzerland)·2026
Same author

Green Ultra-Fast UPLC-MS/MS Method for Enasidenib Quantification in HLMs Matrix With the Metabolic Stability Assessment: In Silico Study for Structural Alerts, ADME Characteristics and Metaboslic Lability.

Biomedical chromatography : BMC·2025

Related Experiment Video

Updated: Mar 3, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic &#946;-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.4K

Propranolol.

Abdulrahman A Al-Majed1, Ahmed H H Bakheit2, Hatem A Abdel Aziz3

  • 1College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Profiles of Drug Substances, Excipients, and Related Methodology
|April 23, 2017
PubMed
Summary
This summary is machine-generated.

This comprehensive profile details propranolol, a noncardioselective beta-blocker. It covers its synthesis, physicochemical properties, and extensive pharmacology for various medical conditions.

Keywords:
DescriptionMethod of analysisPharmacokineticsPhysical characteristicsPropranololSpectral propertiesSynthesis

More Related Videos

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

3.2K
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

12.0K

Related Experiment Videos

Last Updated: Mar 3, 2026

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic &#946;-Blocker
08:32

Disrupting Reconsolidation of Fear Memory in Humans by a Noradrenergic β-Blocker

Published on: December 18, 2014

23.4K
Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

3.2K
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

12.0K

Area of Science:

  • Pharmacology
  • Medicinal Chemistry

Background:

  • Propranolol is a noncardioselective beta-blocker with membrane-stabilizing properties.
  • It lacks intrinsic sympathomimetic activity.
  • Widely used for hypertension, cardiac arrhythmias, and sympathetic overactivity symptoms.

Purpose of the Study:

  • To provide a comprehensive profile of propranolol.
  • To detail its synthesis, physicochemical properties, and analytical procedures.
  • To present in-depth pharmacology, including uses, interactions, and adverse effects.

Main Methods:

  • Characterization using X-ray powder diffraction, pK, solubility, and melting point.
  • Analysis through spectroscopic, electrochemical, and chromatographic methods.
  • Review of pharmacological actions, therapeutic dosing, and clinical applications.

Main Results:

  • Detailed chemical formulas and elemental analysis provided.
  • Physicochemical properties extensively documented.
  • Pharmacological profile covers actions, uses, interactions, and precautions.

Conclusions:

  • Propranolol is a versatile drug with a well-defined profile.
  • The study offers a thorough resource for understanding propranolol's properties and applications.
  • Extensive references support the presented data.